59,322 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Acquired by Corient Private Wealth LP

Corient Private Wealth LP acquired a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) during the second quarter, HoldingsChannel.com reports. The institutional investor acquired 59,322 shares of the company’s stock, valued at approximately $1,065,000.

Several other hedge funds have also added to or reduced their stakes in the stock. Bank of America Corp DE purchased a new stake in shares of Amylyx Pharmaceuticals during the second quarter valued at $14,760,000. Jupiter Topco LLC purchased a new stake in Amylyx Pharmaceuticals in the 2nd quarter worth $94,014,000. Elmind Capital LP purchased a new stake in Amylyx Pharmaceuticals during the second quarter valued at approximately $2,011,520. Hsbc Holdings PLC acquired a new stake in shares of Amylyx Pharmaceuticals during the second quarter worth $269,000. Finally, Canada Pension Plan Investment Board purchased a new stake in Amylyx Pharmaceuticals during the 2nd quarter valued at about $496,000. 95.84% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $18.32, for a total value of $274,800.00. Following the transaction, the insider directly owned 194,090 shares of the company’s stock, valued at approximately $3,555,728.80. This trade represents a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Robert W. Baird lifted their target price on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a research report on Wednesday, August 19th. Guggenheim increased their target price on Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. Citigroup upped their target price on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Mizuho raised their price target on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. Finally, Wall Street Zen cut Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $36.50.

Amylyx Pharmaceuticals Stock Performance

NASDAQ:AMLX opened at $34.10 on Friday. The stock’s 50-day simple moving average is $24.23 and its 200 day simple moving average is $18.18. The company has a market cap of $3.80 billion, a P/E ratio of -23.85 and a beta of -0.13. Amylyx Pharmaceuticals, Inc. has a 52-week low of $9.75 and a 52-week high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.03). As a group, equities analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current fiscal year.

Amylyx Pharmaceuticals Company Profile